At ASM Microbe GeoVax have spoken on the development of single-dose vaccines for emerging diseases using their MVA ‘Plug and Play’ platform technology.
Browsing: Emerging Disease > Ebola
At the recent Microbiology Society Annual Conference (10–12 April, Birmingham, UK) we spoke to Mark Wass about his work on Ebolaviruses in which he’s delved into the molecular determinants of the virus’s pathogenicity.
Two cases of Ebola have been confirmed in Bikoro in the Democratic Republic of Congo, sparking a response from the government and the WHO.
A new study has identified a common pattern of immune response in Ebola-infected monkeys 4 days prior to the development of fever; this response could be utilized as an early diagnosis biomarker.
Researchers have identified that the Ebola virus recruits a host enzyme, PP2A-B56, for replication, demonstrating that inhibiting this pathway could be a target for drug discovery.
Researchers have reported an acceptable safety and immunogenicity profile of an Ebola vaccine in adults and potentially in children in Africa – indicating that the vaccine produces an immune response and is considered safe.
Researchers have examined the cerebrospinal fluid in a small cohort of Ebola survivors, reporting that no viral RNA was present and suggesting the virus may be cell-associated within the CNS.
A live-attenuated Ebola vaccine has demonstrated promising results in a Phase I randomized controlled trial assessing safety and immunogenicity, according to a Canadian study.